The DNA damage caused by “chemo”
The newspapers El Mundo, La Vanguardia and Diari Ara, the TV station TV3 and the radio stationsCatalunya Ràdio andRAC1, among other media, have echoed on a study by the Biomedical Genommics lab, headed by Núria López, published in Nature Genetics. The study has for the first time determined the genetic mutations caused by various therapies used to treat cancer. “Studying the DNA damage caused by chemotherapies in patients’ cells is the first step towards understanding the relation between these mutations and the long-term side effects of these treatments,” says Oriol Pich, PhD student at IRB Barcelona and first author of the article.
Link to El Mundo
Link to La Vanguardia
Link to Diari Ara
Link to CCMM (TV3 y Catalunya Ràdio):
Link to Rac1
Related content
News
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
